Showing results (1-10 of 24) with videos related to
Sort By:
Pageof 3
Gynecologic Oncology|February 28, 2019
Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysisDavid A Barrington, Sarah E Dilley, Haller J Smith, et al.Gynecologic Oncology|April 15, 2022
Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysisDavid A Barrington, Courtney Riedinger, Paulina J Haight, et al.Gynecologic Oncology|July 23, 2022
Implementing universal upfront multi-gene panel testing in endometrial cancer: From cost to practical considerationsMonica D Levine, David A Barrington, Heather Hampel, et al.Journal of Minimally Invasive Gynecology|August 4, 2021
Determinants of Surgical Approach and Survival Among Women with Endometrial CarcinomaKristin Bixel, David A Barrington, Monica H Vetter, et al.Gynecologic Oncology|July 26, 2022
Racial and ethnic disparities in readmission risk following the surgical management of endometrial cancerDavid A Barrington, Caitlin E Meade, Casey M Cosgrove, et al.Gynecologic Oncology|April 26, 2022
Does the addition of radiation improve survival compared to chemotherapy alone in women with stage IV endometrial carcinoma? Analysis of the NCDB and SEER databasesDavid A Barrington, Brandon Fox, Caitlin Meade, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 6, 2020
Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysisDavid A Barrington, Crystal Tubbs, Haller J Smith, et al.Gynecologic Oncology|June 21, 2021
Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysisDavid A Barrington, Paulina J Haight, Cody Calhoun, et al.Gynecologic Oncology|June 13, 2020
Where you live matters: A National Cancer Database study of Medicaid expansion and endometrial cancer outcomesDavid A Barrington, Jennifer A Sinnott, Corinne Calo, et al.Gynecologic Oncology|July 30, 2022
Beyond mismatch repair deficiency? Pre-treatment neutrophil-to-lymphocyte ratio is associated with improved overall survival in patients with recurrent endometrial cancer treated with immunotherapyDavid A Barrington, Corinne Calo, Jae Baek, et al.Pageof 3